ArticleMolecular and clinical oncology2025
Peripheral biomarkers predict survival in patients with glioblastoma treated with temozolomide.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Grade 4 gliomas, including glioblastoma, isocitrate dehydrogenase (IDH)-wild-type [GBM (IDH wt)], and astrocytoma, IDH-mutant, grade 4, are among the most aggressive primary brain tumors. The standard of care for GBM (IDH wt) and astrocytoma, IDH-mutant, grade 4 is maximum safe resection and radiation plus oral temozolomide (TMZ) followed by six cycles of TMZ. The study objective was to identify peripheral biomarkers that predict favorable outcomes and stratify patients likely to respond to treatment. Adults with biopsy-confirmed glioblastoma (based upon the 2016 World Health Organization classification) treated at Beth Israel Deaconess Medical Center (Boston, USA) between January 2018 and November 2021 were identified. Data on laboratory values (white blood cells, absolute neutrophil count, absolute lymphocyte count, red blood cells, hemoglobin and platelet count), molecular markers, including IDH1 R132H and methylguanine-DNA methyltransferase promoter methylation, and progression-free survival (PFS) and overall survival (OS) were collected retrospectively. Data were combined with those from two prior studies, resulting in a total of 263 patients. Leukopenia development during TMZ treatment was associated with increased PFS (P=0.008) and OS (P=0.03). Lymphopenia development during TMZ treatment was associated with increased PFS (P=0.05) and OS (P=0.007). Grade 3 thrombocytopenia during TMZ treatment was associated with decreased PFS (P=0.01) and OS (P=0.02). Patients who developed leukopenia alone during treatment had an increased OS compared with those with only lymphopenia development and those with both lymphopenia and leukopenia development (P=0.007). Lower baseline lymphocyte counts (<0.7 K/µl) prior to treatment was associated with improved OS (P=0.007), while increased baseline neutrophil counts (≥10.0 K/µl) prior to initiation of treatment were associated with worse OS (P=0.002). In conclusion, TMZ exposure may result in a leukocyte predominant bone marrow effect vs. a platelet predominant bone marrow effect. Clinically, leukopenia could indicate adequate TMZ dosing, with thrombocytopenia serving as a limiting factor in the ability to continue TMZ. Baseline counts may offer insights into which patients will benefit the most from treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.